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Background: Hepatocellular adenoma (HCA) larger than 5 cm in diameter has an increased risk of haem-
orrhage and malignant transformation, and is considered an indication for resection. As an alternative to
resection, transarterial embolization (TAE) may play a role in prevention of complications of HCA, but
its safety and efficacy are largely unknown. The aim of this study was to assess outcomes and postem-
bolization effects of selective TAE in the management of HCA.
Methods: This retrospective, multicentre cohort study included patients aged at least 18 years, diagnosed
with HCA and treated with TAE. Patient characteristics, 30-day complications, tumour size before and
after TAE, symptoms before and after TAE, and need for secondary interventions were analysed.
Results: Overall, 59 patients with a median age of 33.5 years were included from six centres; 57 of the
59 patients were women. Median tumour size at time of TAE was 76mm. Six of 59 patients (10 per cent)
had a major complication (cyst formation or sepsis), which could be resolved with minimal therapy, but
prolonged hospital stay. Thirty-four patients (58 per cent) were symptomatic at presentation. There were
no significant differences in symptoms before TAE and symptoms evaluated in the short term (within
3months) after TAE (P= 0⋅134). First follow-up imaging was performed a median of 5⋅5months after
TAE and showed a reduction in size to a median of 48mm (P<0⋅001).
Conclusion: TAE is safe, can lead to adequate size reduction of HCA and, offers an alternative to
resection in selected patients.
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Introduction
Hepatocellular adenoma (HCA) is an uncommon benign
tumour of the liver that mostly occurs in middle-aged
women1,2. Over the past few decades, its rising incidence
has been associated with the widespread use of oral contra-
ceptives and the obesity pandemic1–6. Other less common
aetiologies include use of anabolic androgens, a history of
maturity-onset diabetes of the young and glycogen storage
disease7–11.
HCA is a hypervascular lesion with an exclusively arterial
blood supply, resulting in increased intratumoral pressure,
rendering these tumours susceptible to life-threatening
bleeding3,5,12. The reported risk of spontaneous bleeding
ranges from 20 to 40 per cent13–15. The risk of bleed-
ing is increased in larger-diameter tumours, in tumours
showing exophytic growth, and an increased risk has
also been reported in the sonic hedgehog (sh-HCA) and
inflammatory (I-HCA) subtypes16–24. Malignant trans-
formation into hepatocellular carcinoma (HCC) has been
documented in 4⋅3 per cent of patients with HCA25. An
established risk factor for malignant transformation is an
HCA diameter larger than 5 cm12,18,26. Another important
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risk factor for malignant transformation is a β-catenin
(exon 3) mutation27–29. MRI, as a non-invasive technique,
has become a useful diagnostic tool in identifying HCA
subtypes30,31.
Patients with HCA may experience complaints such as
nausea, pain and tiredness. Although correlation of these
symptoms with the presence ofHCA remains difficult, they
may severely influence patients’ quality of life32. Persis-
tence of these complaints, even when the tumour diameter
does not exceed 5 cm, may be an indication for resection in
selected patients to achieve symptom relief12,16,19,21,33. To
date, elective resection remains the standard treatment for
patients with HCA larger than 5 cm, to prevent potential
bleeding and malignant transformation18,20,21,23. However,
elective liver resection for non-ruptured benign tumours
is associated with a reported major morbidity rate of up
to 7⋅2 per cent34. Transarterial embolization (TAE) offers
an attractive minimally invasive alternative treatment for
non-bleeding HCA35–37. As the majority of patients with
HCA are young, otherwise healthy women, cosmetic out-
comes can be considered important. TAE could be used
in an elective setting to avoid unnecessary resection, in an
open or laparoscopic approach.
Conceptually, tumour regression with a potential reduc-
tion in the risk of bleeding supports the use of TAE as an
elective treatment for HCAs with a diameter of at least
5 cm. The aim of this study was to assess the safety and effi-
cacy of TAE in the management of HCAs, and to describe
its postembolization effects in a multicentre retrospective
cohort study.
Methods
Approval was obtained from the medical ethics committee
of each participating centre. The medical ethics committee
declared this a non-WMO study, which is the Dutch term
for a study that does not directly involve human subjects
through intervention and thus was exempt from formal
ethics approval.
Study design and inclusion
This international retrospective multicentre cohort study
included patients diagnosed with HCA who underwent
TAE between 2001 and 2018 in a collaboration of four
centres participating in the Dutch Benign Liver Tumour
Group (DBLTG). In addition, international data were
accrued from Beaujon Hospital in Paris (France) and
Southampton General Hospital (UK). All participating
centres collected data from patients’ (electronic) records
and charts. All data were processed and stored anony-
mously. Patients were excluded if essential data on the
TAE procedure or outcomes were lacking. The STROBE
guidelines38 were adhered to in this study. Details of data
storage and ethical approval are available in the study pro-
tocol (Appendix S1, supporting information).
Definitions and outcomes
Data on the following patient characteristics were col-
lected: age, sex, BMI, oral contraceptive or steroid use,
co-morbidities associated with HCA, hepatitis B and C
viral status, presence of solitary or multiple tumours, and
the liver segments involved. In addition, information on
the type of imaging used for diagnosis was documented
(contrast-enhanced (CE) MRI, MRI without contrast,
CE-CT, CT without contrast, and regular ultrasound
examination). Data on subtype of HCA based on imag-
ing, subtype based on assessment of biopsy or resection
specimen, and molecular subtype based on molecular
diagnostics were collected. Subtypes were noted as a
baseline characteristic, but not used in subgroup analyses
owing to the limited number of patients available for this
study. When no material for pathology was present, HCA
subtype was determined based on CE-MRI. Subtypes were
classified as steatotic (H-HCA), inflammatory (I-HCA),
β-catenin-activated (β-HCA), and combined inflammatory
and β-catenin-activated HCA (β-IHCA)39,40; sh-HCA
could not be identified because molecular diagnostics for
this subtype had not yet been implemented at time of
diagnosis of most patients. Unclassified adenomas were
adenomas for which no subtype could be determined. Data
on the presence of bleeding (clinical, subclinical, bleeding
after biopsy), indication for TAE (elective because of size,
elective because of symptoms, elective because of (impend-
ing) bleeding, acute because of bleeding or poor surgical
candidate) and management (TAE, surgery after TAE,
radiofrequency ablation (RFA) and TAE combined, TAE
and RFA combined followed by surgery) were collected.
The type of embolization agent used was also recorded.
Primary outcomes
The primary outcome measures were safety, defined
as procedure-related morbidity consisting of postem-
bolization syndrome (right upper quadrant pain, fever,
nausea/vomiting)41, decrease in renal function42, sepsis
(life-threatening organ dysfunction caused by a dysreg-
ulated host response to infection)43, and adverse events
(abscess formation, bleeding, malignant transformation).
Complications were graded according to the Society of
Interventional Radiology Classification System for Com-
plications by Outcome (SIR)44. Minor complications were
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classified as: A, no therapy, no consequence; and B, nominal
therapy, no consequence, including overnight admission
for observation only. Major complications were classified
as: C, requiring therapy, minor hospital admission (less
than 48 h); D, requiring major therapy, unplanned increase
in level of care, prolonged hospital stay (48 h or more);
E, permanent adverse sequelae; and F, death. Duration of
hospital stay was also recorded.
Secondary outcomes
The secondary outcomes related to efficacy: the short-term
effects of TAE on symptoms and size of both bleeding
and non-bleeding HCAs. To this end, data on symptoms
before and within 3months after TAE were obtained.
In addition, any decrease in tumour size was registered;
tumour size was defined as the diameter of the largest
tumour present. Tumour size was measured at diagnos-
tic imaging, last imaging before TAE, first follow-up after
TAE and last follow-up. Tumour growth or regression was
assessed using the Response Evaluation Criteria in Solid
Tumours (RECIST)45. Large (intra)tumoral haematomas
were not included in total tumour size. If adenomatous tis-
sue was not visible in the HCA because of haematoma,
the patient was not included in this study. The overall
success rate was based on how often surgery was pre-
vented by TAE. The following data were recorded for
patients who subsequently underwent surgery: indication
for surgery, symptoms before and after surgery, type of
surgery, perioperative and postoperative complications,
duration of hospital stay and the occurrence of incisional
hernias. All outcomes were analysed in two categories: for
bleeding (confirmed on imaging, being the indication for
TAE) and non-bleeding HCAs.
Statistical analysis
Outcomes were reported for the complete cohort, and
stratified according to whether the tumour was bleeding.
Categorical data are presented as proportions; continu-
ous data are reported as mean(s.d.) if normally distributed,
and as median (i.q.r.) if not. Normality was assessed using
both Kolmogorov–Smirnov and Shapiro–Wilk tests for
normality. Values for asymmetry and kurtosis of between
–2 and+ 2 were considered acceptable as proof of normal
univariable distribution46. The Wilcoxon signed-rank test
was used for analysis of data without a normal distribu-
tion (tumour size), and McNemar’s test for paired nomi-
nal data (symptoms before and after surgery). Two-tailed
P< 0⋅050 was considered statistically significant. SPSS®
for Windows® version 24.0 (IBM, Armonk, New York,
USA) was used.
Results
Overall, 60 patients were identified, of whom 59 met the
inclusion criteria (Table 1). Twenty-three patients under-
went TAE to treat a bleeding HCA, and 36 had elective
TAE for a non-bleeding HCA. One patient was excluded
because portal vein embolization was reported and not
TAE. Overall, median age was 33⋅5 years and 57 of 59
patients (97 per cent) were women. Median tumour size
at the time of diagnosis was 84mm, 85mm for bleeding
HCAs and 83mm for non-bleedingHCAs.Median tumour
size measured just before TAE was 76mm overall, 82mm
for bleeding HCAs and 70mm for non-bleeding lesions
(Fig. 1); these measurements were made 5⋅7months after
diagnosis, and were not significantly different from those
obtained at the time of diagnosis. Themost frequently used
embolization agent was polyvinyl alcohol in the bleeding
group (9 of 23), whereas microspheres were most com-
monly used in the non-bleeding group (14 of 36).
Safety of transarterial embolization
Seven of 59 patients (12 per cent) had complications,
of whom six (10 per cent) had an SIR D complication
(Table S1, supporting information). Of these, two patients
developed an intrahepatic cyst, which required drainage
because of infection. Two other patients developed sepsis,
which was treated successfully with supportive care includ-
ing antibiotics. One patient died 3months after TAE; this
patient underwent emergency TAE for a bleeding HCA
because of haemorrhagic shock. After TAE, the patient
was transferred to the ICU of another hospital, but subse-
quently developed aspiration pneumonia and died. Further
details of this patient were not available owing to anony-
mous data collection and lack of consent to obtain individ-
ual data from the other hospital. During follow-up after
TAE, no patient experienced clinically overt bleeding or
rebleeding of a treated HCA. Postembolization syndrome
(right upper quadrant pain, fever, nausea/vomiting) was
observed in one patient, which resolved without interven-
tion. No clinically relevant disturbances of liver function
tests were reported. Short-term pain occurred after TAE
in ten patients (17 per cent).
Symptoms before and after transarterial
embolization
There were no significant differences in the overall inci-
dence of symptoms before TAE compared with short-term
evaluation within 3months of TAE (58 versus 37 per cent;
P= 0⋅134). Nor were any significant differences noted
before and after TAE in the bleeding and non-bleeding
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Table 1 Baseline characteristics in patients with bleeding and non-bleeding hepatocellular adenomas
Overall (n= 59) Bleeding (n= 23) Non-bleeding (n= 36)
Age (years)* 33⋅5 (26⋅1–41⋅2) 34⋅4 (25⋅0–42⋅7) 32⋅7 (26⋅7–39⋅9)
BMI (kg/m2)* 29⋅8 (25⋅3–37⋅9) 30⋅1 (26⋅3–32⋅0) 28⋅7 (24⋅3–39⋅5)
Tumour size at diagnosis (mm)* 84 (59–100) 85 (58–100) 83 (57–106)
Sex ratio (F :M) 57 : 2 23 : 0 34 : 2
Oral contraceptive
Stopped at time of diagnosis 43 (73) 18 (78) 25 (69)
Stopped before diagnosis 10 (17) 4 (17) 6 (17)
Unknown 4 (7) 1 (4) 3 (8)
Anabolic steroids 1 (2) 0 (0) 1 (3)
Never used 1 (2) 0 (0) 1 (3)
Co-morbidities
Diabetes mellitus type I 3 (5) 2 (9) 1 (3)
Diabetes mellitus type II 2 (3) 1 (4) 1 (3)
MODY 3 1 (2) 0 (0) 1 (3)
Glycogen storage disease 1 (2) 0 (0) 1 (3)
Insulin resistance and PCOS 1 (2) 0 (0) 1 (3)
None 51 (86) 20 (87) 31 (86)
Viral status
Hepatitis B-positive† 2 (3) 1 (4) 1 (3)
Hepatitis C-positive 0 (0) 0 (0) 0 (0)
Tumour pattern
Solitary 24 (41) 8 (35) 16 (44)
Multiple 35 (59) 15 (65) 20 (56)
Tumour location
Both 30 (51) 14 (61) 16 (44)
Right 19 (32) 6 (26) 13 (36)
Left 9 (15) 2 (9) 7 (19)
Unknown 1 (2) 1 (4) 0 (0)
Imaging
CE-MRI 50 (85) 18 (78) 32 (89)
CE-CT 4 (7) 3 (13) 1 (3)
Ultrasound imaging and CE-CT 4 (7) 1 (4) 3 (8)
Ultrasound imaging 1 (2) 1 (4) 0 (0)
Molecular subtype‡
HCA – subtype not specified 33 (56) 18 (78) 15 (42)
I-HCA 15 (25) 4 (17) 11 (31)
H-HCA 5 (8) 0 (0) 5 (14)
β-IHCA 3 (5) 0 (0) 3 (8)
U-HCA 1 (2) 1 (4) 0 (0)
Uncertain diagnosis 1 (2) 0 (0) 1 (3)
I-HCA+HCC 1 (2) 0 (0) 1 (3)
Bleeding
No bleeding 28 (47) 0 (0) 28 (78)
Clinical bleeding 20 (34) 20 (87) 0 (0)
Subclinical bleeding 6 (10) 1 (4) 5 (14)
Bleeding after biopsy 5 (8) 2 (9) 3 (8)
Indication for TAE§
Size, elective 31 (53) 0 (0) 31 (86)
Haemorrhage, acute 19 (32) 19 (83) 0 (0)
Haemorrhage, elective 4 (7) 4 (17) 0 (0)
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Table 1 continued
Overall (n= 59) Bleeding (n= 23) Non-bleeding (n= 36)
Symptoms 4 (7) 0 (0) 4 (11)
Poor surgical candidate 1 (2) 0 (0) 1 (3)
Management
TAE 36 (61) 14 (61) 22 (61)
TAE then surgery 19 (32) 6 (26) 13 (36)
TAE and RFA 3 (5) 2 (9) 1 (3)
TAE and RFA then surgery 1 (2) 1 (4) 0 (0)
Embolic agent
PVA 22 (37) 9 (39) 13 (36)
Microspheres 16 (27) 2 (9) 14 (39)
(Platinum) coils 6 (10) 5 (22) 1 (3)
Gelatine sponge/foam 3 (5) 2 (9) 1 (3)
Foam + PVA 3 (5) 2 (9) 1 (3)
Coils + microspheres 1 (2) 1 (4) 0 (0)
Unknown 8 (14) 2 (9) 6 (17)
Values in parentheses are percentages unless indicated otherwise; *values aremedian (i.q.r.). †One hepatitis B-positive patient had suspicion of hepatocellular
carcinoma (HCC). ‡Based on histopathological analysis, and, if unavailable, on MRI. §Thirty-five of 36 patients in the non-bleeding group had tumours
larger than 5 cm.MODY, maturity-onset diabetes of the young; PCOS, polycystic ovary syndrome; CE, contrast-enhanced; HCA, hepatocellular adenoma;
I-HCA, inflammatory HCA; H-HCA, steatotic HCA; β-IHCA, combined inflammatory and β-catenin-activated inflammatory HCA; U-HCA, unclassified
HCA; TAE, transarterial embolization; RFA, radiofrequency ablation; PVA, polyvinyl alcohol.
Fig. 1 Median tumour size before and after transarterial embolization
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*P< 0⋅001 versus before transarterial embolization (TAE) (Wilcoxon signed-rank test).
groups (Table 2). A flow chart summarizing the relief of pre-
procedural complaints and development of new complaints
is shown in Fig. 2.
Outcomes of transarterial embolization
and surgery
Data on TAE and surgical intervention are presented in
Table 3. Most patients received only a single session of TAE
(36 of 59, 61 per cent). Median overall duration of hospital
stay after TAE was 3 days; patients with a bleeding HCA
had a significantly longer hospital stay than those with a
non-bleeding tumour (median 12 versus 2 days; P= 0⋅013).
One-third of patients (20 of 59) required resection fol-
lowing initial TAE. Sixteen of these patients had received
one session of TAE, whereas three patients had undergone
multiple sessions; the number of TAE sessions was not
reported for one patient.
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Table 2 Symptoms before and after transarterial embolization
Overall (n=59) Bleeding (n=23) Non-bleeding (n=36)
Before TAE After TAE P* Before TAE After TAE P* Before TAE After TAE P*
Short-term symptoms 34 (58) 22 (37) 0⋅134 17 (74) 8 (35) 0⋅109 17 (47) 14 (39) 0⋅774
Pain 27 (46) 15 (25) 15 (65) 3 (13) 12 (33) 12 (33)
None 16 (27) 24 (41) 5 (22) 9 (39) 11 (31) 15 (42)
Multiple 5 (9) 1 (2) 1 (4) 0 (0) 4 (11) 1 (3)
Nausea 1 (2) 2 (3) 1 (4) 2 (9) 0 (0) 0 (0)
Tiredness 0 (0) 4 (7) 0 (0) 3 (13) 0 (0) 1 (3)
Missing 10 (17) 13 (22) 1 (4) 6 (26) 9 (25) 7 (19)
Values in parentheses are percentages. TAE, transarterial embolization. *McNemar’s test for paired nominal data.
Fig. 2 Patients with symptoms before and after transarterial embolization
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The newly developed complaints among seven patients who were asymptomatic before transarterial embolization (TAE) lasted for only a short time. In 15
patients who were symptomatic before TAE, complaints either persisted or were replaced by short-term complaints; five of these 15 patients had short-term
complaints only.
Efficacy of transarterial embolization
Changes in tumour size during follow-up are reported
in Fig. 1, and Fig. S1 and Table S2 (supporting informa-
tion). Overall median tumour size at the time of TAE was
76mm. First follow-up imaging a median of 5⋅5months
after TAE (Table S3, supporting information) showed a
reduction in tumour size of 37 per cent, to a median of
48mm (P< 0⋅001). At last follow-up imaging, a median
of 27⋅4months after TAE, tumour size had reduced by
41 per cent to a median of 45mm (P< 0⋅001). Diagnosis
and subtypes are summarized in Table S4 (supporting
information).
In the subgroup analyses, bleeding HCAs showed similar
regression, from 82mm at the time of TAE, to 47mm
(43 per cent reduction) at first follow-up (18 patients)
(P< 0⋅001), and 41mm (50 per cent reduction) at the end
of follow-up (12 patients) (P< 0⋅001). A similar pattern
was observed in the subgroup of non-bleeding HCAs;
median size was 70mm at the time of TAE, decreasing
to 51mm (27 per cent reduction) at first follow-up (35
patients) (P< 0⋅001), and 45mm (36 per cent reduction) at
last follow-up (21 patients) (P< 0⋅001).
Of 36 patients (61 per cent) who had no procedure other
than TAE during the study interval, 28 had a tumour
of 5 cm or larger before embolization. The tumour had
decreased to smaller than 5 cm in 17 of the 36 patients
after 6months, and in 27 patients by last follow-up. No
significant differences were found regarding size reduction
and regrowth after TAE for the different embolization
agents (Table S5, supporting information).
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
on behalf of BJS Society Ltd.
Transarterial embolization of hepatocellular adenomas
Table 3 Outcomes of transarterial embolization and surgery
Overall (n= 59) Bleeding (n= 23) Non-bleeding (n= 36)
TAE
No. of sessions required
1 36 (61) 13 (57) 23 (64)
2 6 (10) 2 (9) 4 (11)
3 5 (8) 2 (9) 3 (8)
4 1 (2) 0 (0) 1 (3)
Not reported 11 (19) 6 (26) 5 (14)
Duration of hospital stay (days)* 3⋅0 (1⋅0–10⋅5) 12⋅0 (4⋅8–18⋅3) 2⋅0 (1⋅0–5⋅0)
Surgery 20 (34) 7 (30) 13 (36)
Indication for surgery
Persisting size 9 (45) 1 (14) 8 (62)
Bleeding 4 (20) 4 (57) 0 (0)
HCC suspected 3 (15) 1 (14) 2 (15)
Growth 2 (10) 0 (0) 2 (15)
Persisting symptoms 1 (5) 0 (0) 1 (8)
Pregnancy wish 1 (5) 1 (14) 0 (0)
Type of surgery
Open segment resection 9 (45) 4 (57) 5 (38)
Open hemihepatectomy 6 (30) 2 (29) 4 (31)
Laparoscopic hemihepatectomy 5 (25) 1 (14) 4 (31)
Perioperative complications
None 18 (90) 6 (86) 12 (92)
Bleeding 2 (10) 1 (14) 1 (8)
Postoperative complications
None 14 (70) 3 (43) 11 (85)
Bleeding (Clavien–Dindo I) 2 (10) 2 (29) 0 (0)
Abscess (Clavien–Dindo III) 2 (10) 2 (29) 0 (0)
Thrombosis (Clavien–Dindo II) 1 (5) 0 (0) 1 (8)
Thrombosis and sepsis (Clavien–Dindo II) 1 (5) 0 (0) 1 (8)
Duration of hospital stay (days)* 10⋅0 (7⋅5–11⋅0) 10⋅0 (10⋅0–41⋅0) 8⋅0 (4⋅0–10⋅0)
Incisional hernia† 2 (10) 1 (14) 1 (8)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †All symptomatic. TAE, transarterial embolization.
Malignant transformation
Two patients had an uncertain diagnosis on histopatho-
logical assessment. The histopathology report stated that
a lesion resected before TAE was an I-HCA/highly differ-
entiated HCC in one patient. This patient had multiple
tumours in both liver lobes, and underwent embolization
of the remaining lesions, which could not be removed
during surgery. No material was available for pathological
analysis of these tumours. Although the previous pathol-
ogy report suggested the presence of I-HCA/HCC, the
clinical course of this patient was uneventful after TAE.
The remaining lesions regressed after TAE, no metastasis
developed, there were no paraneoplastic signs or raised
tumour marker levels, and the patient was still alive after
a follow-up of 4 years with no signs of disease. In the
other patient, an uncertain diagnosis of HCA or HCC was
based on indistinctive pathological features after hemi-
hepatectomy. This patient was a male body builder and
anabolic steroid user, who received TAE for treatment
of an HCA in the other liver lobe. Two other patients
with biopsy-proven β-HCA underwent TAE and showed
no signs of malignant transformation or regrowth during
follow-up, after 40 and 39months respectively.
Discussion
This study has shown that TAE for large HCA is rela-
tively safe and potentially effective in decreasing tumour
size, as tumours decreased to approximately half their
size after treatment. This decrease was also clinically rel-
evant, as the tumour was smaller than 5 cm in diameter
after embolization in the majority of patients, so did not
require resection. The results warrant a prospective study
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to compare outcomes of TAE with those of (minimally
invasive) surgery in the management of HCA.
A systematic review42 comprising 151 patients (95 with
non-bleeding tumours) who underwent TAE for the treat-
ment of HCA identified no deaths. Complete regression
on imaging of the tumour was observed in 10 per cent
of patients, and a decrease of more than 30 per cent of
the tumour diameter in 75 per cent. The review, however,
could not distinguish size reduction between bleeding and
non-bleeding tumours42. The authors of a small study47
proposed that bleeding of an HCA leads to size reduc-
tion, possibly because of tumour disruption and subsequent
destruction of the adenomatous tissue. This may imply that
the effect of TAE on regression is merely based on the
bleeding event. Therefore, to assess the overall effect of
TAE on size reduction, bleeding and non-bleeding HCAs
were compared in the present study. A similar size reduc-
tion was seen in both groups.
Whether the decrease in size also reduces the risk of
malignant transformation is subject to speculation. Suspi-
cion of malignancy was the reason for resection in some
patients in this study, but malignancy could not be excluded
in only one male patient. Nomalignant transformation was
observed in two patients with β-HCA after TAE who were
followed up for 40 and 39months respectively. However,
as these patients represent the only cases of β-HCA treated
with TAE to be reported in the literature so far, the impli-
cations of positive β-catenin status after biopsy in regard
with treatment with TAE are unknown.
The question remains whether biopsy should be per-
formed routinely preceding TAE to identify β-HCA,
especially as molecular diagnostics are now available.
However, there are also disadvantages to routine biopsy,
such as bleeding, needle-track tumour seeding (both of
which carry a small risk) and sampling error.
Whether TAE helps to relieve complaints in symp-
tomatic patients remains uncertain. No differences in
symptoms beforeTAE andwithin 3months after emboliza-
tion were found in this study. This is surprising, especially
considering that patients with an acute bleeding HCA usu-
ally present with severe pain. Although it might be assumed
that stopping the bleeding would relieve complaints, a
counterargument could be that the haematoma remains in
patients with intracapsular bleeding. However, there was a
trend suggesting relief of symptoms in the bleeding sub-
group in the present study, although differences were not
statistically significant.
A limitation of this study is that no validated question-
naire was used and only symptoms developing within
3months of TAE were evaluated. Newly developed
complaints could therefore not be distinguished from
pre-existing ones as some patients crossed over from the
asymptomatic to the symptomatic group after final treat-
ment (Fig. 2). Moreover, it is unclear whether any new
complaints were transient or not. Pain developing after
TAE was most likely caused by intratumoral ischaemia
induced by TAE. This should subside after necrosis of the
tumour is complete. Follow-up of at least 1 year is nec-
essary to assess the long-term impact of TAE on relief of
symptoms, using a validated quality-of-life questionnaire.
An alternative to both surgery and TAE could be local
ablation of the HCA. Percutaneous image-guided ablation
is less invasive than open or laparoscopic surgery. Benefits
and harms of percutaneous ablation in patients with HCA
have never been assessed in a prospective cohort study, and
the largest retrospective study48 included only 18 patients.
The complications that occurred in the latter study were
mainly formation of cysts because of necrosis. These com-
plications were resolved readily using routine therapeutic
interventions. Moreover, percutaneous ablation is typically
performed in tumours smaller than 4 cm because of the risk
of incomplete ablation49,50. The majority of HCAs with an
indication for intervention exceed 5 cm, but it is uncertain
whether incomplete ablation of HCA is an issue. An advan-
tage of TAE is that application is not limited by tumour size
or location.
Another limitation of the present study is the lack of
a control group. Ideally, patients should be randomized
between TAE and sham TAE to assess the true effect of
TAE on relief of complaints. To assess the effect on tumour
size, however, randomization is not strictly necessary, as a
placebo effect will not influence tumour size after TAE.
The control group in the study by Klompenhouwer and
colleagues51 could be used as a surrogate group when
considering tumour size; these authors reported regression
of HCA during conservative management. However, in the
present series, HCA treated with TAE showed a larger
decrease in size than the conservatively managed HCA
reported by Klompenhouwer et al.51.
A strength of the present study is the national and inter-
national collaboration between centres participating in the
DBLTG. This collaboration resulted in an increase in vol-
ume and in the number of specialized centres involved in
the field of benign liver tumours, increasing the quality of
the study. A further strength of this study is its clinical rele-
vance; TAE as primary treatment of HCA has the potential
to be considered in future guidelines.
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